Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer.
We assessed antitumor activity and toxic effects of cisplatin and 5-day continuous infusion vinblastine in 25 evaluable patients with metastatic breast carcinoma refractory to one or more chemotherapeutic regimens. We administered cisplatin at 70 mg/m2 i.v. followed by vinblastine 1.5 mg/m2 daily for five consecutive days. In our heavily pretreated, poor performance patient population, we observed one complete response and four partial responses, with a median time to progression of 35 weeks. Toxic effects were significant and prevented dosage escalation. The addition of cisplatin does not appear to improve the therapeutic value of vinblastine alone.
Fraschini
G
G
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
Holmes
F A
FA
Buzdar
A U
AU
Hug
V
V
Hortobagyi
G N
GN
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D014747:Vinblastine; D002945:Cisplatin